Nahleh, Z. A. http://orcid.org/0000-0002-2489-1501
Barlow, W. E.
Hayes, D. F.
Schott, A. F.
Gralow, J. R.
Sikov, W. M.
Perez, E. A.
Chennuru, S.
Mirshahidi, H. R.
Corso, S. W.
Lew, D. L.
Pusztai, L.
Livingston, R. B.
Hortobagyi, G. N.
Funding for this research was provided by:
National Institutes of Health (CA180888, CA180819, CA180821, CA180835, CA180830, CA180846, CA180801, CA180834; NIH/NCI Community Oncology Research Program (NCORP) grants CA189954, CA189856, CA189971, CA189822, CA189952, CA189804, CA189817, CA189953, CA189858, CA189957, CA189872, CA189853; legacy NIH/NCI grants CA35119, CA52654, CA04919, CA37981, CA58416, CA16385)
Genentech
Roche
Abraxis
Article History
Received: 23 June 2016
Accepted: 25 June 2016
First Online: 8 July 2016
Compliance with ethical standards
:
: All remaining authors have declared that they have no conflicts of interest to report.
: Employment: E. Perez: Genentech; Stock or other ownership: E. Perez: Genentech; D. Hayes: Oncimmune LLC, De Soto, KS, USA, and Inbiomotion, Barcelona, Spain; Consulting or advisory role: J. Gralow: Novartis, Roche/Genentech; G. Hortobagyi: Lilly USA, LLC, Celgene, Norvartis, Merck, Bayer and Peregrine Pharmaceuticals, Inc; H. Mirshahidi: Clovis Oncology, Boehringer; D. Hayes: Pfizer Global Advisory Board for pablociclib; W. Sikov: Abbvie, Celgene (uncompensated) Honoraria: L. Pusztai: Celgene; D. Hayes: Lecture/Honorarium as a Visiting Consultant for Lilly Oncology, Indianapolis, IN; W Sikov: Eisai, Celgen Research funding: J. Gralow: Novartis, Roche/Genentech; L. Pusztai/institution/clinical trial support: D. Hayes: Sponsored Clinical Research—Principle or co-Investigator: Merrimack Pharmaceuticals, Inc. (Parexel Intl Corp), Eli Lilly Company, Janssen R&D, LLC (Johnson & Johnson), Veridex (Johnson & Johnson), Puma Biotechnology, Inc., (subcontract Wash Univ St. Louis to Univ Mich), Pfizer, Astra Zeneca, Astra Zeneca; Travel, accommodations or expenses: L. Pusztai/self: Celgene Royalties: D. Hayes: Royalties from licensed technology: Janssen R&D, LLC (Johnson & Johnson); Patents: D. Hayes: Title: A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells. Filed 14 Mar 2005 with the European Patent Office, Netherlands. Application No./Patent No. 05725638.0-1223-US2005008602. Applicant/Proprietor: Immunicon Corporation. Dr. Daniel F. Hayes is designated as inventor/coinventor. Title: Diagnosis and Treatment of Breast Cancer. Patent No.: US 8,790,878 B2. Date of Patent: Jul. 29, 2014. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/coinventor. Title: Circulating Tumor Cell Capturing Techniques and Devices. Patent No.: US 8,951,484 B2. Date of Patent: Feb. 10, 2015. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/coinventor.